H84T and D133G BanLec purification. Briefly, to produce non-His-tagged proteins, cleared lysates were added to a Sephadex G-75 column that had been equilibrated with PBS. The column was then washed with PBS until the OD of the flow-through at 280 nm was less than 0.02. Elution of the protein was then performed using 0.2 M methyl a-D-glucopyranoside. For all lectins, endotoxin testing was performed using the Pierce LAL Chromogenic Endotoxin Quantitation Kit (Thermo Fisher Scientific). Endotoxin removal was performed by adding glucose to a 1 M concentration and passing pooled eluates containing protein through Mustang E filters (Pall). Following endotoxin removal to < 0.1 endotoxin units/mg of protein, the Vivaspin 20 centrifugal unit with 3K MWCO was used to remove glucose and concentrate the lectin in water. Protein and endotoxin concentrations were then measured by BCA and LAL assays, respectively.
added to RBCs, H84T-RBC mixture was added to virus, or the H84T-virus and H84T-RBC mixtures were added together in 96-well V-bottom plates. Three dilutions of A/WSN/1933 (H1N1) virus were used (1:8, 1:16, and 1:32). Plates were gently tapped to mix and then incubated for 30 min at room temperature. Hemagglutination was assessed visually.
Virus-cell fusion assay. Viral fusion to the cell membrane was triggered at 37ºC using fusion buffer (150 mM NaCl solution with 25 mM HEPES, Corning) at pH ~5.25. Fluorescence dequenching of R18 was monitored on a microplate fluorometer with excitation and emission wavelengths of 560 and 590 nm, respectively. Maximal dequenching was achieved with 1% Triton X-100 set at 100%.
Pharmacokinetics of single dose intraperitoneal (IP) H84T. Plasma and lung sample processing:
Blood samples (0.5-1 ml) were collected via cardiac puncture tubes and deposited into K3 EDTA tubes and mice euthanized at 0, 5, 15, and 30 minutes and 1, 2, 4, 8, 24, 48 , and 72 hours post-dose (n = 4 per time point) for collection of liver and lungs. Blood samples were placed on ice and centrifuged at 2500 rpm for 10 minutes under refrigerated conditions, after which plasma was collected and frozen at -80ºC within 1 hour of collection. Liver and lungs were rinsed with 0.9% sodium chloride, blotted dry, and weighed. Mouse lung tissue was weighed (5 mg) and homogenized in 1mL of PBS with 1M glucose and complete EDTA free protease inhibitor cocktail. The homogenized tissue was incubated on ice for 1 h to allow greater extraction of H84T and centrifuged at 10,000 rpm for 10 min at 4ºC. The supernatant was transferred to clean 1.5 mL vials and cleared by centrifuging again at 15,000 rpm for 10 minutes at 4ºC. ELISA: Standard curves were prepared in duplicate in mouse plasma or lung homogenate and quality control samples analyzed in addition to unknown samples. 96-well Nunc MaxiSorp plates (Thermo Fisher Scientific) were coated with 100 ng of capture antigen, HIV gp120, and sealed and incubated overnight at 4ºC. The capture antigen was aspirated and discarded, and the wells were washed 3 times with wash buffer (0.05% Tween-20 in PBS). The wells were blotted dry, filled with blocking buffer (3% BSA in PBS), and incubated at room temperature (RT) for 2 h. After 3 more washes, 100 µl mouse plasma or processed mouse lung tissue supernatant were added to each well and the plate was incubated at RT for 1 h on a mini blot rocker. The wells were washed with wash buffer 6 times and the primary antibody (rabbit polyclonal anti-BanLec at 1:25,000) in blocking buffer was added and incubated at RT for 1 h on a mini blot rocker. The wells were then washed with wash buffer 8 times and secondary antibody (biotinylated goat anti-rabbit at 2 µg/ml) in blocking buffer was added and incubated for 30 min at RT on a mini blot rocker. The wells were washed with wash buffer 8 times and detection antibody (high sensitivity HRPconjugated streptavidin, 1:200 for plasma and 1:400 for lung) was added and incubated at room temperature for another 30 min on a mini blot rocker. After a final set of 8 washes, the substratechromogen TMB was added and incubated at room temperature for 10-20 min in the dark. The reaction was stopped by the addition of stopping solution (0.5M H2SO4) and read at 450 nm on a plate reader. The following PK parameters were calculated using the Phoenix WinNonLin Non-compartmental Analysis program, version 6.4.0.768: maximum concentration, Cmax (ng/ml or ng/g); time at which maximum concentration occurs, Tmax (hrs); area under the curve, AUC (ng*hrs/ml); half-life, t1/2 (hrs).
Distribution of single dose intraperitoneal (IP) H84T.
Mice were culled at 4 time points post injection (6h, 12h, 24h, and 48h) and lungs, liver, kidneys, heart, spleen, and brain harvested and snap frozen. Frozen organs were homogenized on dry ice by mortar and pestle and protein extraction performed in the presence of protease inhibitors. Protein extracts were separated by 4-20% SDS-PAGE and immunoblotted using rabbit anti-BanLec polyclonal antibody and HRP-conjugated anti-rabbit secondary antibody.
Therapeutic efficacy of systemic H84T against influenza in BALB/c mice. Animals: Female 18-20 g BALB/c mice were obtained from Charles River Laboratories (Wilmington, MA). Virus: Recombinant influenza A/WSN/33 (H1N1) virus containing the HA gene of influenza A/New Caledonia/20/99 (H1N1) was generated by reverse genetics. The Asp225Gly mutation was introduced in the HA gene encoding the HA1 subunit by PCR based site-directed mutagenesis by Dr. Larissa Gubareva (CDC, Atlanta, GA). The recombinant virus was designated influenza A/WSN/33 HAnc-Asp225Gly (H1N1) and became lethal after 7 serial passages in the lungs of animals. Virus was plaque purified and a virus stock was prepared by growth on MDCK cells. In each study, five non-treated normal control mice were maintained for weight comparison. For influenza virus challenge, mice were anesthetized by IP injection of ketamine/xylazine (50 mg/kg//5 mg/kg) prior to challenge by the intranasal route with approximately 5 x 10 3 (2 x LD50) cell culture infectious doses (CCID50) (IP efficacy) or 1 x 10 3 CCID50 (SC efficacy) of virus per mouse in a 90 µl inoculum volume. Mice were weighed prior to treatment and then every other day thereafter to assess the effects of treatment on ameliorating weight loss due to virus infection. All mouse groups were observed for morbidity and mortality through day 21 post-infection.
Therapeutic efficacy of intranasal H84T against H3N2 influenza virus. Mouse-adapted influenza A/Hong Kong/8/1968 (H3N2) virus was kindly provided by Dr. Brian E. Gilbert, Baylor College of Medicine. Frozen stock (2.8 x 10 7 50% tissue culture infective doses [TCID50]/ml) of virus was diluted 1:250 in 0.05% gelatin in Eagle's minimal essential medium and delivered by aerosolization for 20 min to achieve the 90% lethal dose (LD90) to LD100 (~100 TCID50 per mouse) in wild type six-week-old C57BL/6J mice of a single sex. Animals were examined and weighed daily and sacrificed if they met euthanasia criteria, including signs of distress or loss of 30% preinfection body weight. Mice were treated daily for 5 days beginning 4 hours post-infection with 40 µL intranasal PBS (sham) or H84T BanLec (0.1 mg/kg) without anesthesia. Quantitation of immunofluorescence staining. The number of punctae and percent overlap were calculated using ImageJ software first by converting individual color channel images to grayscale, then by converting them to binary (black and white only) images. The Analyze Particles function was used to calculate the number of particles in each individual color channel, followed by the Image Calculator function to calculate the number of particles with overlap between color channels. The percent overlap was calculated by dividing the number of overlapping particles by the number of particles in a particular color channel as described in the relevant figure legends. The diameter of punctae was calculated by using the Measure tool to assess pixel length. At least three micrographs per group were used for each quantitation. Error bars denote the standard error of the mean of technical triplicate values. Statistical analyses were performed by t test using the Holm-Sidak method. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, and *****P < 0.00001, comparing the H84T to the D133G groups for each HA type (gray asterisks = H3, black asterisks = H1). 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
